N Verses Capital, LLC Intra Cellular Therapies, Inc. Transaction History
N Verses Capital, LLC
- $219 Billion
- Q3 2024
A detailed history of N Verses Capital, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, N Verses Capital, LLC holds 3,900 shares of ITCI stock, worth $331,461. This represents 0.13% of its overall portfolio holdings.
Number of Shares
3,900Holding current value
$331,461% of portfolio
0.13%Shares
1 transactions
Others Institutions Holding ITCI
# of Institutions
378Shares Held
84.7MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$818 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$537 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$449 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$327 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$259 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $8.02B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...